GYN

Mercy's Susan T. Peeler, M.D., and Patricia McMullen, WHNP, named Winners of inaugural Interprofessional Humanism in Healthcare Award

Retrieved on: 
Thursday, January 4, 2024
Woman, Health, Catholic higher education, BSN, Humanism, Collaboration, The Institute, MBA, Dean, University, Practitioner, FAAN, Family, DRS, Physician, JD, Catholic University of America, WHNP-BC, Hysteroscopy, Maryland School, WHNP, CNS, Patient, Mercy Hospital, Colposcopy, Gold, Partnership, GYN, AACN, Doctor of Philosophy, MD, FACOG, RN, Organization, Nursing

BALTIMORE, Jan. 4, 2024 /PRNewswire-PRWeb/ -- The Arnold P. Gold Foundation and the American Association of Colleges of Nursing (AACN) have announced the winners of the inaugural AACN-Gold Interprofessional Humanism in Healthcare Award, a new honor that celebrates and elevates the collaboration of physicians and nurses.Susan Todd Peeler, M.D., FACOG, MBA, and Patricia McMullen, PhD, JD, CNS, WHNP-BC, were recognized in December 2023 for their partnership in supporting comprehensive women's healthcare and disseminating best practices on women's health to clinicians across a wide range of disciplines.

Key Points: 
  • Mercy's Susan T. Peeler, M.D., and Patricia McMullen, WHNP, have been named recipients of the inaugural AACN-Gold Interprofessional Humanism in Healthcare Award, a new honor that celebrates and elevates the collaboration of physicians and nurses.
  • The Institute provides routine women's healthcare, as well as services for complex gynecological issues for women of all ages.
  • The new award will be centered each year on a theme, which this year is "Innovations in Interprofessional Collaboration that Drive Humanism in Healthcare."
  • Peeler and McMullen will be presented with the AACN-Gold Interprofessional Humanism in Healthcare Award at the 2024 Gold Humanism Summit in Atlanta, Georgia.

MedVanta Announces Partnership with Physicians Surgery Center of Frederick   

Retrieved on: 
Thursday, July 6, 2023
Podiatry, Partnership, GYN, AAAHC, Private practice, Medicare, Operating, Patient, Physician, Nursing, Ophthalmology, MSK, General surgery, MSO, Health, Dentistry

"We are thrilled to partner with Physicians Surgery Center of Frederick, a group that shares our commitment to preserving independence and delivering the highest standard of care at an efficient price.

Key Points: 
  • "We are thrilled to partner with Physicians Surgery Center of Frederick, a group that shares our commitment to preserving independence and delivering the highest standard of care at an efficient price.
  • Through this partnership, Physicians Surgery Center of Frederick will have access to MedVanta's full suite of next-generation MSO and technology services and will initially focus on streamlining billing and revenue cycle management.
  • Founded in 2002, Physicians Surgery Center of Frederick employs over 35 physicians, nurses, surgical technicians, and staff.
  • The 6,300 square-foot facility provides patients convenient and cost-efficient surgical services including general surgery, orthopaedic surgery and podiatry, cosmetic and reconstructive surgery, GYN services, oculoplastic surgery, oral maxillofacial surgery and more.

Sofinnova Investments Appoints Dr. Jakob Dupont as Executive Partner

Retrieved on: 
Tuesday, May 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Other Health, Memorial Sloan Kettering Cancer Center, GYN, Therapy, Senior, Investment, OncoMed, Stanford University, Vassar College, Clinical trial, Breast, Panasonic Executive Partner, Inflammation, Antibody, Assistant, Oncology, Philosophy, Patient, University, Internal medicine, Pleasure, MSK, IND, Joan, ADC, Hospital, R, Cornell University, Pharmaceutical industry, New York University

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Jakob Dupont, M.D., to the investment team as an Executive Partner.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Jakob Dupont, M.D., to the investment team as an Executive Partner.
  • Dr. Dupont brings more than two decades of experience in the field of oncology and other therapeutic areas, in developing therapies and programs dedicated to addressing high unmet medical needs.
  • Through his industry career he has contributed to 12 regulatory approvals and 13 successful IND filings.
  • “We’ve had the pleasure of knowing Jakob for a number of years, he has had a broad impact across the healthcare landscape, and we are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.

Olympus Technologies Featured in Several Experience Papers on Energy Advancements

Retrieved on: 
Monday, January 23, 2023
Smoke, Electrosurgery, Otorhinolaryngology, General surgery, Nursing, UltraVision, Dissection, Association of periOperative Registered Nurses, Health care, Olympus, ENT, Becker, Surgeon, Pain, FACS, Jaw, Patient, Duke University Health System, GYN, Assistant, Female, Bariatric surgery, CO2, Clinical, DO, Icahn School of Medicine at Mount Sinai, Workflow, Division, Oncology nursing, University, Perioperative, Energy, Epako Women's Center, News, Rectum, Physician, Mount Sinai, AORN, Risk, Peter Hancock (professor), Dentistry, MD, Laparoscopy

CENTER VALLEY, Pa., Jan. 23, 2023 /PRNewswire/ -- Olympus announced today the availability of several Experience Papers focused on the benefits of advancements in electrosurgical devices. Important to the broad range of minimally invasive surgical solutions available to patients, electrosurgical or "energy" devices are designed to allow for efficient dissection and cauterization of tissue. Many times, as explained in these papers, they also contribute to improved workflow in the procedure room. Among these papers developed for a healthcare professional audience, benefits of workflow, ergonomics, cost reduction and control of energy-related smoke were discussed.

Key Points: 
  • Important to the broad range of minimally invasive surgical solutions available to patients, electrosurgical or "energy" devices are designed to allow for efficient dissection and cauterization of tissue.
  • Many times, as explained in these papers, they also contribute to improved workflow in the procedure room.
  • Among these papers developed for a healthcare professional audience, benefits of workflow, ergonomics, cost reduction and control of energy-related smoke were discussed.
  • More information about the Olympus Energy devices included in these Experience Papers can be found here:

Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update

Retrieved on: 
Monday, January 9, 2023
ISU, European Medical Writers Association, PARK, MDR, PMDA, Image, CE marking, Digital, Leonardo da Vinci, Operation Time, GYN, Anatomy, Surgeon, NYSE, 3D, Kitakyushu, U.S. FDA, Growth, Acceleration, Patient, Urology, Sale, General surgery, Freedom, RESEARCH, Gynaecology, TRUST, CIS, Investment, Dentistry, Medical device, Security (finance), Video game, Medicine

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update.
  • During the fourth quarter of 2022, the Company initiated five new Senhance Surgical System placements, two in Germany, two in Japan, and one in the CIS region.
  • In 2022, the Company initiated nine new Senhance Surgical System placements: four in Germany, three in Japan, and two in the CIS region.
  • For the quarter ended December 31, 2022, the Company estimates preliminary unaudited revenue of approximately $2.2 - $2.8 million.

Fed Court Declares Newsom's Actions Against AHF Unconstitutional

Retrieved on: 
Monday, November 28, 2022
AIDS, Public Policy, Government, Health, State, Local, Health Insurance, Managed Care, Housing, GYN, Food, California Department of Health Care Services, Sacramento County Superior Court, Patient, Testimonial, First Amendment to the United States Constitution, DHCS, Writ, AHF, Speech, Letter, AIDS, First, PHC, AIDS Healthcare Foundation, District of Columbia Voting Rights Amendment, HIV, MCP, Health insurance, Lease, Mildred Vorpahl Baass

When I went to AIDS Healthcare Foundation, they embraced me with loving arms and wanted to help me to survive.

Key Points: 
  • When I went to AIDS Healthcare Foundation, they embraced me with loving arms and wanted to help me to survive.
  • In late June 2022, however, AHF received notice from DHCS that it was NOT renewing AHFs contract for the plan for 2023.
  • AHF also filed a Petition for Writ of Mandate in Sacramento Superior Court seeking to halt DHCSs cancellation of the contract.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth , follow us @aidshealthcare or subscribe to our AHF podcast AHFter Hours.

Promaxo Announces Research Collaboration with the University of Montreal Hospital Research Centre (CRCHUM) for Improved Prostate, Female GYN Cancer Management

Retrieved on: 
Thursday, September 15, 2022
Adult, GYN, Health, Radiation, Gynaecology, Twitter, General Hospital, Canada, CHUM, Prostate, Company, MRI, Fonds, Partnership, CHU, Government, Health Canada, CEO, Technology, Student, Chair, Female, Public health, Doctor of Philosophy, Diagnosis, Robotics, Associate, École Polytechnique, Research, Prostate cancer, GLOBE, University, Jewish General Hospital, AI, Obstetrics, Brachytherapy, Medical imaging, MD, Physics

With this technology, we expect to improve the accuracy of image-guidance for needle navigation and brachytherapy, leading to improved patient outcomes in the future.

Key Points: 
  • With this technology, we expect to improve the accuracy of image-guidance for needle navigation and brachytherapy, leading to improved patient outcomes in the future.
  • With proven expertise in brachytherapy physics and medical imaging development, he will lead a team of students and scientists for this collaboration.
  • The University of Montreal Hospital Research Centre (CRCHUM) is one of North Americas leading hospital research centres.
  • The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay

Retrieved on: 
Thursday, August 18, 2022
Endometriosis, CEO, GLOBE, FACS, FACOG, Eastern Time Zone, Annual report, Bethesda Hospital, Patient, Detection, KOL, MD, Health, Risk, Private Securities Litigation Reform Act, Congress, Life, Innovation, OB, Gynaecology, Doctor of Philosophy, Physician, Ovarian cancer, Art in the US Women's Suffrage Movement, Bethesda, GYN, Solution, JCO, FDA, Woman, Biomarker, Genetic testing, Steven Naifeh, Risk assessment, University, Medicine, Birth control, Medical device, Mensa International, Aspira

AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira), a bio-analytical based womens health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on womens health and ovarian cancer risk assessments utilizing multivariant index assays on Wednesday, August 24, 2022 at 12:00pm Eastern Time.

Key Points: 
  • AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira), a bio-analytical based womens health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on womens health and ovarian cancer risk assessments utilizing multivariant index assays on Wednesday, August 24, 2022 at 12:00pm Eastern Time.
  • He will discuss how Aspiras soon-to-be-launched OVAWatchTM multivariate index assay diagnostic risk assessment may benefit women with pelvic masses who are not planned for surgery.
  • About Aspira Womens Health Inc.
    Aspira Womens Health Inc. is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.
  • Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.

Total Testing Solutions Partners with OmniPathology to Offer Oral HPV Testing in Los Angeles

Retrieved on: 
Tuesday, August 16, 2022
Woman, Ear, Risk, CEO, Population, Cancer, HPV, Man, Male, COVID-19, West LA Courthouse skate plaza, Marie Cassidy, Nose, Partnership, TTS, Vaccination, MPH, Occupational Safety and Health Act 1994, Esophageal cancer, ENT, GYN, Colon, Pathology, Patient, Solution, Total, STI, Health, Medical imaging, Vaccine, Pharmaceutical industry

LOS ANGELES, Aug. 16, 2022 /PRNewswire/ -- Total Testing Solutions (TTS), a Los Angeles-based medical diagnostic testing company has announced a partnership with private lab, OmniPathology to offer oral HPV testing in the LA area. This state-of-the-art testing is now available at the West LA TTS site (10830 Santa Monica Blvd., Century City). Additional TTS locations will begin offering the service in the coming weeks.

Key Points: 
  • LOS ANGELES, Aug. 16, 2022 /PRNewswire/ -- Total Testing Solutions (TTS), a Los Angeles-based medical diagnostic testing company has announced a partnership with private lab, OmniPathology to offer oral HPV testing in the LA area.
  • "We are so thrilled to be partnering with OmniPathology to add HPV testing to our offerings at TTS," says Lauren Trenkle, CEO of Total Testing Solutions.
  • "We are extremely excited about collaborating with Total Testing Solutions to offer our oropharyngeal HPV PCR test.
  • OmniPathology considers TTS a perfect partner in making our Oral HPV PCR test available to the public," said Mohammad Kamal, MD Founder and CEO of OmniPathology.

OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test

Retrieved on: 
Tuesday, July 12, 2022
Infection, Male, Smoking, Man, Centers for Disease Control and Prevention timeline, Human papillomavirus infection, Science, ENT, Colon, Risk, Patient, CEO, Center, Ear, Risk factor, GLOBE, Physician, STI, LDT, Nose, Oral, Pathology, Health, GYN, Woman, Immune system, Esophageal cancer, Cancer, HPV, CDC, Dentist, Vaccine

The Oral HPV Test is a lab-developed test (LDT) performed on a Roche cobas 6800 and 8800 high-throughput platforms.

Key Points: 
  • The Oral HPV Test is a lab-developed test (LDT) performed on a Roche cobas 6800 and 8800 high-throughput platforms.
  • The Oral HPV Test detects 14 high-risk strains of HPV.
  • Launching this oropharyngeal HPV test is an exciting milestone for OmniPathology, especially since this is an underserved area for diagnostic testing.
  • For more information about the new Oral HPV Test, please contact OmniPathology at http://omnipathology.com/closer-look .